Celgene Corp | StockChase
52
Celgene Corp (CELG-Q)

Last Price Recorded: $105.1600 on 2017-11-23

ON STOCKCHASE SINCE Jan 2012

Consumer Products

Celgene Corp


Signal Opinion Expert

2017-11-16

WAIT
Celgene Corp (CELG-Q)

One of the larger biotech companies. The big drop last month was due to a halt in one of their trials where they were developing what looked like a pretty good drug which would have been a big market. He would stay away for another month or so, but longer-term, it is a pretty good company with a portfolio of good drugs in development and good drugs in the market.

Consumer Products
Alex Ruus

Portfolio Manager, Arrow Capital Management

Price: $103.350
Owned: Unknown

2017-11-13

PAST TOP PICK
Celgene Corp (CELG-Q)

(A Top Pick April 19/17. Down 18%.) Was one of the hottest stocks in the medical space. They have a plethora of new products in front of the FDA. It caught a cliff when 3 events happened. It was getting close to his target price of $150. One of the major analysts cut their price target which knocked it into the $130 range. FDA didn’t approve one of the new drugs knocking the price down into the $120 range. Missed a little on the 3rd quarter, so it dropped into the $100 range. He still likes it and is still buying.

Consumer Products
Bruce Murray

CEO & Chief Investment Officer, The Murray Wealth Group

Price: $101.160
Owned: Yes

2017-11-10

PAST TOP PICK
Celgene Corp (CELG-Q)

(A Top Pick Nov 30/16. Down 14%.) Reported earlier this month. Just prior to reporting, took a phase 3 drug out of the pipeline, that had a lot of promise. It was a drug that treated Crohn’s disease. It will build back some of the confidence, but it will take time. The return opportunities are good enough to continue holding the position.

Consumer Products
Gordon Reid

President, GoodReid Investment Counsel

Price: $102.340
Owned: Yes

2017-10-20

BUY
Celgene Corp (CELG-Q)

This is revisiting old highs, which is a very bullish sign. In this case, it actually broke above its old highs. The current correction seems very healthy as long as it continues making higher lows. Add to your position, but keep a Stop at around $110.

Consumer Products
William Chin

Portfolio manager, Caldwell Investment Management

Price: $121.330
Owned: Unknown

2017-09-20

PAST TOP PICK
Celgene Corp (CELG-Q)

(A Top Pick Oct 4/16. Up 38%.) One of the outstanding growth stocks in the US medical field. They have a plethora of new drugs coming out. Sales are growing at about 25% per annum. With the current earnings, the target price could move into the $165-$170 due to the growth rate. The company is more likely to surprise on the upside and another $1 of earnings could give you a $20-$25 a share. This could be a $200 stock. Still a Buy.

Consumer Products
Bruce Murray

CEO & Chief Investment Officer, The Murray Wealth Group

Price: $144.240
Owned: Yes

2017-09-19

TOP PICK
Celgene Corp (CELG-Q)

This has done extremely well. It is growing quickly. Has a good pipeline with 4 drugs that he believes could be $1 billion or more in revenue. The biggest property they own is Revlimid. They concentrate on cancer treating drugs. Not inexpensive, but is reasonably priced. Thinks that next year they will do $8 a share in earnings, less than 20X, and growing at a rapid rate. (Analysts’ price target is $156.)

Consumer Products
Gordon Reid

President, GoodReid Investment Counsel

Price: $143.470
Owned: Yes

2017-09-14

PAST TOP PICK
Celgene Corp (CELG-Q)

(Top Pick Feb 22/17, Up 19%).  They have a blood cancer drug.  They are testing it on all kinds of other indications.  They have the ability to double the revenues based on their existing products.  It is the more growthy component of his portfolio.

Consumer Products
Paul Macdonald

Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group

Price: $140.610
Owned: Yes

2017-08-09

COMMENT
Celgene Corp (CELG-Q)

This is big and is more diversified than others, so you are not buying a binary outcome stock. He likes biotech, but would approach it from the equal weight standpoint by going through the SPDR S&P Biotech ETF (XBI-N). Celgene is a good name.

Consumer Products
Cameron Hurst

Chief Investment Officer, Equium Capital Management

Price: $135.570
Owned: Unknown

2017-08-01

PAST TOP PICK
Celgene Corp (CELG-Q)

(A Top Pick Oct 4/16. Up 28.79%.) Still loves this and has a target price of about $160 2-3 years out. It has some great products and has a whole plethora of new products before the FDA.

Consumer Products
Bruce Murray

CEO & Chief Investment Officer, The Murray Wealth Group

Price: $135.180
Owned: Yes

2017-07-31

COMMENT
Celgene Corp (CELG-Q)

Biotech stocks do really well this time of year from June 23 until September 13. Since 2002 they have been positive 88% of the time, and outperformed the S&P 500 88% of the time. July tends to be the best month for biotech stocks. The chart shows higher lows and a little bit of a break out. From a technical standpoint, this is positive. Very often, he will sell his biotech stocks later on in August.

Consumer Products
Brooke Thackray

President, Jov Investment Management

Price: $135.410
Owned: Unknown

2017-07-25

PAST TOP PICK
Celgene Corp (CELG-Q)

(A Top Pick July 6/16. Up 31.77%.) This is still a Buy. It has cancer drugs that work. Very, very profitable. Amazing balance sheet. Very, very strong management team.

Consumer Products
John O'Connell, CFA

Chairman and CEO, Davis Rea

Price: $136.440
Owned: Yes

2017-06-14

PAST TOP PICK
Celgene Corp (CELG-Q)

(A Top Pick July 6/16. Up 16%.) Biotechnology company involved in cancer drugs. 20% earnings growth. Trading at 14X earnings. Strong balance sheet. Still a buy.

Consumer Products
John O'Connell, CFA

Chairman and CEO, Davis Rea

Price: $121.040
Owned: Yes

2017-06-02

PARTIAL BUY
Celgene Corp (CELG-Q)

He likes this. It closed at $116.41, and his model price is $145.80, a 25% upside. Maybe this gets down to $97, which would be an absolute Buy. Buy half a position now, and when it went cheaper, Buy the other half.

Consumer Products
Brian Acker, CA

Chief Executive Officer, President and Chief Inves, Acker Finley Inc.

Price: $118.730
Owned: Yes

2017-05-29

TOP PICK
Celgene Corp (CELG-Q)

They are growing nicely.  One of the fastest growing large cap pharma in North America.  Their slowest growth year was 14%.  Otherwise they averaged 20% per year over the last 10 years.  (Analysts’ target: $147) .

Consumer Products
Teal Linde

Portfolio Manager & Publisher, Linde Equity Report, Linde Equity Report

Price: $116.780
Owned: Yes

2017-05-26

PAST TOP PICK
Celgene Corp (CELG-Q)

(A Top Pick April 6/16. Up 8%.) Their cancer drug continues to do well. They have a strong pipeline behind that. The shares are trading at 15X forward earnings, with what he expects to be a 20% long-term growth rate. That gives a PEG ratio of .75. Still very cheap.

Consumer Products
Stan Wong

Director & Portfolio Manager, Private Wealth Management, ScotiaMcleod

Price: $116.780
Owned: Yes

Showing 1 to 15 of 52 entries
<< < 1 2 3 4 > >>

No Comments.


You must be logged in to comment.